Cargando…
Safety, pharmacokinetics and pharmacodynamics of the anti‐hepcidin Spiegelmer lexaptepid pegol in healthy subjects
BACKGROUND AND PURPOSE: Anaemia of chronic disease is characterized by impaired erythropoiesis due to functional iron deficiency, often caused by excessive hepcidin. Lexaptepid pegol, a pegylated structured l‐oligoribonucleotide, binds and inactivates hepcidin. EXPERIMENTAL APPROACH: We conducted a...
Autores principales: | Boyce, M, Warrington, S, Cortezi, B, Zöllner, S, Vauléon, S, Swinkels, D W, Summo, L, Schwoebel, F, Riecke, K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4842915/ https://www.ncbi.nlm.nih.gov/pubmed/26773325 http://dx.doi.org/10.1111/bph.13433 |
Ejemplares similares
-
Randomized double-blind placebo-controlled PK/PD study on the effects of a single intravenous dose of the anti-hepcidin Spiegelmer NOX-H94 on serum iron during experimental human endotoxemia
por: Van Eijk, L, et al.
Publicado: (2013) -
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study
por: Ludwig, H, et al.
Publicado: (2017) -
The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects
por: Stavros, Fiona, et al.
Publicado: (2010) -
Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects
por: Dolder, Patrick C., et al.
Publicado: (2017) -
Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects
por: Li, Yinhua, et al.
Publicado: (2021)